---
title: Allergan Receives FDA Approval for Migraine Treatment
description: Allergan Receives FDA Approval for Migraine Treatment
---

[News ](https://www.yourway.com/news)

# [Allergan Receives FDA Approval for Migraine Treatment](https://www.yourway.com/news/allergan-receives-fda-approval-for-migraine-treatment)

 Written by [Yourway](https://www.yourway.com/news/author/yourway) | January 9, 2020

UBRELVY™ is the first and only orally-administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the treatment of migraine attacks. The [therapy](https://www.allergan.com/News/Details/2019/12/Allergan%20Receives%20US%20FDA%20Approval%20for%20UBRELVY%20for%20the%20Acute%20Treatment%20of%20Migraine%20with%20or%20without%20Au) is taken by the user once a migraine starts — UBRELVY then provides relief for up to 24 hours. Yourway supports a patient-centric supply chain so that drugs in clinical trials can reach patients faster, regardless of where they are located.

[View full post](https://www.yourway.com/news/allergan-receives-fda-approval-for-migraine-treatment)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Yourway"
  },
  "dateModified" : "2020-01-09T10:00:00.314Z",
  "datePublished" : "2020-01-09T10:00:00Z",
  "headline" : "Allergan Receives FDA Approval for Migraine Treatment",
  "image" : {
    "@type" : "ImageObject",
    "height" : 1845,
    "url" : "https://cdn2.hubspot.net/hubfs/5402331/News%20and%20Articles%20Banners/yourway_news_010920.jpg",
    "width" : 3879
  },
  "mainEntityOfPage" : "https://www.yourway.com/news/allergan-receives-fda-approval-for-migraine-treatment",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "News"
  }
}
```